RNA Analytical/Quality Videos

  1. The Evolutions Of mRNA Analytical Development (So Far) 8/22/2024

    Linear mRNA analytical development has been rapidly advancing in the past few years and this panel discussion explores some of the biggest changes we’ve seen in the linear mRNA analytical paradigm.

  2. How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today? 2/10/2025

    In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?

  3. Must-Have CDMO Capabilities And MSA Make-Or-Breaks For mRNA-LNP Outsourcing 2/10/2025

    Three Advancing RNA Live panelists share their greatest needs in outsourcing partnerships for mRNA/RNA-LNP products and where sponsors should be the most prescriptive when drafting an MSA with an outsourcing partner.

  4. In Which Specific Areas Do mRNA Makers Need More Regulatory Guidance? 5/10/2024

    Experts from this Advancing RNA Live panel discuss the results from a poll question revealing the top three areas RNA industry experts would be most interested in seeing additional mRNA-specific guidance from regulatory agencies.

  5. Validation Of mRNA Concentration Determination 8/20/2023

    mRNA-based therapeutics require comprehensive analytical testing to meet regulatory requirements. Optimize processes and ensure fast and reliable results as you bring your product to market.

  6. Nanoassemblr Blaze mRNA Vaccine Demo 4/13/2022

    NxGen Technology delivers a scalable means to perform the critical particle formation step in a nanomedicine development process.

  7. Your Roadmap For Efficient Processes 3/4/2025

    Struggling with mRNA integrity? Discover essential strategies to boost stability in mRNA manufacturing with innovative endonuclease-free DTT and Spermidine chemicals.

  8. Decoding Regulatory Expectations: The Art Of A Successful IND Submission 6/24/2025

    Companies often underestimate the information required for IND submissions, particularly in a sector that’s as diverse as the mRNA sector. Here, former FDA reviewer Tiffany Lucas shares some of the missteps companies can make when first approaching the FDA with their IND. CureVac’s Ulrike Jägle furthers the discussion, offering a critical best practice she and her colleagues rely upon as well to streamline their regulatory interactions.

  9. CMC Innovations Worth Watching In The RNA-LNP Space 12/4/2024

    Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.

  10. How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic 1/31/2023

    Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.